Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Invested Capital: 2020-2025

Historic Invested Capital for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to $165.1 million.

  • SAB Biotherapeutics' Invested Capital rose 347.32% to $165.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $165.1 million, marking a year-over-year increase of 347.32%. This contributed to the annual value of $26.0 million for FY2024, which is 54.68% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Invested Capital stood at $165.1 million for Q3 2025, which was up 1,273.76% from $12.0 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Invested Capital high stood at $165.1 million for Q3 2025, and its period low was $12.0 million during Q2 2025.
  • Its 3-year average for Invested Capital is $44.0 million, with a median of $28.1 million in 2023.
  • The largest annual percentage gain for SAB Biotherapeutics' Invested Capital in the last 5 years was 347.32% (2025), contrasted with its biggest fall of 73.95% (2025).
  • Over the past 5 years, SAB Biotherapeutics' Invested Capital (Quarterly) stood at $42.5 million in 2021, then decreased by 18.02% to $34.8 million in 2022, then skyrocketed by 64.56% to $57.3 million in 2023, then crashed by 54.68% to $26.0 million in 2024, then skyrocketed by 347.32% to $165.1 million in 2025.
  • Its Invested Capital stands at $165.1 million for Q3 2025, versus $12.0 million for Q2 2025 and $21.4 million for Q1 2025.